从COVID-19大流行中吸取的教训:鼻内给药作为一种治疗途径-专利审查。

IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Nicole Menezes Pinto, Marcos Rafael das Chagas Mendonça, Jeferson da Silva Santos, Camilla Martins Dos Santos Ferraz, Daniela Santos Oliveira, Lívia Vilas Boas Dos Santos, Adriano Antunes de Souza Araújo, Lucindo José Quintans Júnior, Divaldo Pereira Lyra Júnior, Alfredo Dias de Oliveira Filho, Ana Amélia Moreira Lira, Mairim Russo Serafini, Rogéria de Souza Nunes
{"title":"从COVID-19大流行中吸取的教训:鼻内给药作为一种治疗途径-专利审查。","authors":"Nicole Menezes Pinto, Marcos Rafael das Chagas Mendonça, Jeferson da Silva Santos, Camilla Martins Dos Santos Ferraz, Daniela Santos Oliveira, Lívia Vilas Boas Dos Santos, Adriano Antunes de Souza Araújo, Lucindo José Quintans Júnior, Divaldo Pereira Lyra Júnior, Alfredo Dias de Oliveira Filho, Ana Amélia Moreira Lira, Mairim Russo Serafini, Rogéria de Souza Nunes","doi":"10.1080/10837450.2025.2487575","DOIUrl":null,"url":null,"abstract":"<p><p>The COVID-19 pandemic exposed the fragility of today's marketed treatments for respiratory infections. As a primary site of infection, the upper airways may represent a key access route for the control and treatment for these conditions. The present study aims to explore and identify, through a patent review, the novelty of therapies for COVID-19 that use the intranasal route for drug administration. A search was carried out in Wipo and Espacenet, using the descriptors 'COVID-19 OR SARS-CoV 2' AND 'treatment OR therapy' AND NOT 'vaccine OR immunizing' and the classification 'A61K9/0043'. Of the 151 patents identified, we excluded 73 duplicates, and 36 documents that meet the criteria adopted for exclusion (not nasally administered formulations, vaccines, post COVID-19 treatments, uncertain route of administration or form). We identified 78 unique patents on patent databases, of which 42 were selected for this review. The documents revealed the use of the intranasal pathway not only for drug repositioning but also for using plant-derived and biological molecules. Overall, the new formulations explore a variety of known drugs and natural products incorporated in drug carrier systems and devices for drug delivery and administration. Thus, the intranasal route remains a promising strategy for drug delivery, offering direct access to the primary infection site and warranting further exploration.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1-17"},"PeriodicalIF":2.6000,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lessons learned from the COVID-19 pandemic: the intranasal administration as a route for treatment - a patent review.\",\"authors\":\"Nicole Menezes Pinto, Marcos Rafael das Chagas Mendonça, Jeferson da Silva Santos, Camilla Martins Dos Santos Ferraz, Daniela Santos Oliveira, Lívia Vilas Boas Dos Santos, Adriano Antunes de Souza Araújo, Lucindo José Quintans Júnior, Divaldo Pereira Lyra Júnior, Alfredo Dias de Oliveira Filho, Ana Amélia Moreira Lira, Mairim Russo Serafini, Rogéria de Souza Nunes\",\"doi\":\"10.1080/10837450.2025.2487575\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The COVID-19 pandemic exposed the fragility of today's marketed treatments for respiratory infections. As a primary site of infection, the upper airways may represent a key access route for the control and treatment for these conditions. The present study aims to explore and identify, through a patent review, the novelty of therapies for COVID-19 that use the intranasal route for drug administration. A search was carried out in Wipo and Espacenet, using the descriptors 'COVID-19 OR SARS-CoV 2' AND 'treatment OR therapy' AND NOT 'vaccine OR immunizing' and the classification 'A61K9/0043'. Of the 151 patents identified, we excluded 73 duplicates, and 36 documents that meet the criteria adopted for exclusion (not nasally administered formulations, vaccines, post COVID-19 treatments, uncertain route of administration or form). We identified 78 unique patents on patent databases, of which 42 were selected for this review. The documents revealed the use of the intranasal pathway not only for drug repositioning but also for using plant-derived and biological molecules. Overall, the new formulations explore a variety of known drugs and natural products incorporated in drug carrier systems and devices for drug delivery and administration. Thus, the intranasal route remains a promising strategy for drug delivery, offering direct access to the primary infection site and warranting further exploration.</p>\",\"PeriodicalId\":20004,\"journal\":{\"name\":\"Pharmaceutical Development and Technology\",\"volume\":\" \",\"pages\":\"1-17\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-04-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceutical Development and Technology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10837450.2025.2487575\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Development and Technology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10837450.2025.2487575","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

2019冠状病毒病大流行暴露了目前已上市的呼吸道感染治疗方法的脆弱性。作为感染的主要部位,上呼吸道可能是控制和治疗这些疾病的关键途径。本研究旨在通过专利审查,探索和确定使用鼻内给药途径治疗COVID-19的新颖性。在Wipo和Espacenet中进行了检索,使用描述符“COVID-19或SARS-CoV 2”和“治疗或治疗”,而不是“疫苗或免疫”,分类为“A61K9/0043”。在确定的151项专利中,我们排除了73项重复专利和36份符合排除标准的文件(非鼻腔给药制剂、疫苗、COVID-19后治疗、不确定的给药途径或形式)。我们在专利数据库中发现了78项独特专利,其中42项被选为本次综述的专利。这些文件揭示了鼻内通路不仅用于药物重新定位,而且用于使用植物源性和生物分子。总的来说,新配方探索了多种已知药物和天然产物纳入药物载体系统和设备,用于药物输送和给药。因此,鼻内途径仍然是一种有前途的药物递送策略,提供直接进入原发感染部位的途径,值得进一步探索。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Lessons learned from the COVID-19 pandemic: the intranasal administration as a route for treatment - a patent review.

The COVID-19 pandemic exposed the fragility of today's marketed treatments for respiratory infections. As a primary site of infection, the upper airways may represent a key access route for the control and treatment for these conditions. The present study aims to explore and identify, through a patent review, the novelty of therapies for COVID-19 that use the intranasal route for drug administration. A search was carried out in Wipo and Espacenet, using the descriptors 'COVID-19 OR SARS-CoV 2' AND 'treatment OR therapy' AND NOT 'vaccine OR immunizing' and the classification 'A61K9/0043'. Of the 151 patents identified, we excluded 73 duplicates, and 36 documents that meet the criteria adopted for exclusion (not nasally administered formulations, vaccines, post COVID-19 treatments, uncertain route of administration or form). We identified 78 unique patents on patent databases, of which 42 were selected for this review. The documents revealed the use of the intranasal pathway not only for drug repositioning but also for using plant-derived and biological molecules. Overall, the new formulations explore a variety of known drugs and natural products incorporated in drug carrier systems and devices for drug delivery and administration. Thus, the intranasal route remains a promising strategy for drug delivery, offering direct access to the primary infection site and warranting further exploration.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.90
自引率
2.90%
发文量
82
审稿时长
1 months
期刊介绍: Pharmaceutical Development & Technology publishes research on the design, development, manufacture, and evaluation of conventional and novel drug delivery systems, emphasizing practical solutions and applications to theoretical and research-based problems. The journal aims to publish significant, innovative and original research to advance the frontiers of pharmaceutical development and technology. Through original articles, reviews (where prior discussion with the EIC is encouraged), short reports, book reviews and technical notes, Pharmaceutical Development & Technology covers aspects such as: -Preformulation and pharmaceutical formulation studies -Pharmaceutical materials selection and characterization -Pharmaceutical process development, engineering, scale-up and industrialisation, and process validation -QbD in the form a risk assessment and DoE driven approaches -Design of dosage forms and drug delivery systems -Emerging pharmaceutical formulation and drug delivery technologies with a focus on personalised therapies -Drug delivery systems research and quality improvement -Pharmaceutical regulatory affairs This journal will not consider for publication manuscripts focusing purely on clinical evaluations, botanicals, or animal models.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信